Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jingmaiyan granules for acute thrombophlebitis
CTR20230143Phase 2Completed
- Sponsor
- Shanghai Tufeng Pharmaceutical Technology Co., Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Superficial Phlebitis comparing Jingmaiyan granules with Placebo (2 arms). Started Jan 2023; status: completed.
02
Drugs
Jingmaiyan Granules
03
Conditions
Superficial Phlebitis
Beyond the preview
Go deeper on CTR20230143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230143.